Lars Soerensen - Novo Nordisk CEO
NONOF Stock | USD 126.50 0.95 0.75% |
CEO
Mr. Lars Rebien Soerensen no longer serves as Chief Executive Officer and President at Novo Nordisk AS effective as of by the end of 2016 . He was CEO since November 2000 and he has served as President of the Company since April 2015. He also served as President of the Company from November 2000 until January 30 2014. He joined the Company Enzymes Marketing in 1982. Over the years he was stationed in several countries including the Middle East and the United States. He was appointed Member of Corporationrationrate Management in May 1994 and was given responsibility for Health Care within Corporationrationrate Management in December 1994. He is Vice Chairman of the Boards of Directors of Carlsberg AS. He received the French award Chevalier de lOrdre National de la Legion dHonneur in 2005. Since October 2007 he was Adjunct Professor at the Faculty of Life Sciences of Koebenhavns Universitet . He holds a MS degree in Forestry from Koebenhavns Universitet from 1981 and a BS degree in International Economics from Copenhagen Business School from 1983. since 2015.
Age | 60 |
Tenure | 9 years |
Phone | 45 44 44 88 88 |
Web | https://www.novonordisk.com |
Novo Nordisk Management Efficiency
The company has return on total asset (ROA) of 0.2169 % which means that it generated a profit of $0.2169 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.72 %, meaning that it generated $0.72 on every $100 dollars invested by stockholders. Novo Nordisk's management efficiency ratios could be used to measure how well Novo Nordisk manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 8 records | CEO Age | ||
Paul Perreault | CSL Limited | 60 | |
Lars Joergensen | Novo Nordisk AS | 54 | |
Leonard Schleifer | Regeneron Pharmaceuticals | 65 | |
Paul Perreault | CSL | 60 | |
MD FASN | Vertex Pharmaceuticals | 50 | |
Lars Jorgensen | Novo Nordisk AS | 58 | |
Robert Moscato | Moderna | 41 | |
David Domzalski | Vyne Therapeutics | 57 |
Management Performance
Return On Equity | 0.72 | |||
Return On Asset | 0.22 |
Novo Nordisk AS Leadership Team
Elected by the shareholders, the Novo Nordisk's board of directors comprises two types of representatives: Novo Nordisk inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novo. The board's role is to monitor Novo Nordisk's management team and ensure that shareholders' interests are well served. Novo Nordisk's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novo Nordisk's outside directors are responsible for providing unbiased perspectives on the board's policies.
Soeren Pedersen, Director, Employee Representative | ||
Doug Langa, Senior Vice President Head of North America Operations and Presidentident of Novo Nordisk Inc. | ||
Jakob Riis, Executive VP of China, Pacific and Marketing and Member of Executive Management | ||
Kasim Kutay, Director | ||
Jesper Brandgaard, CFO, Executive Vice President | ||
Sylvie Gregoire, Director | ||
Mette Jensen, Director, Employee Representative | ||
Mary Szela, Director | ||
Jerzy Gruhn, Executive Vice President Europe | ||
Douglas Langa, Head VP | ||
Eivind Kolding, Director | ||
Kasper Poulsen, Head of Investor Relations, Corporate Vice President | ||
Thomas Rantzau, Director, Employee Representative | ||
Lars Jorgensen, CEO Pres | ||
Karsten Knudsen, CFO, Executive Vice President | ||
Lars Joergensen, Executive Vice President CIO | ||
Helge Lund, Director | ||
Martin Lange, Head VP | ||
Maziar Doustdar, Executive Vice President International Operations | ||
Brian Daniels, Director | ||
Goran Ando, Chairman of the Board | ||
Martin Mackay, Director | ||
Jeppe Christiansen, Vice Chairman of the Board | ||
Bruno Angelici, Independent Director | ||
Liselotte Hyveled, Director, Employee Representative | ||
Anne Kverneland, Director, Employee Representative | ||
Kaare Schultz, President COO | ||
Liz Hewitt, Independent Director | ||
Jesper Hoeiland, Executive Vice President US | ||
Ludovic Helfgott, Executive Vice President of Biopharm | ||
Camilla Sylvest, Executive Vice President Commercial Strategy & Corporate Affairs | ||
Mads Thomsen, Chief Science Officer, Executive VP and Member of Executive Management | ||
Andreas Fibig, Director | ||
Monique Carter, Head VP | ||
Peter Ankersen, Corporate Vice President & Head of Investor Relations | ||
Laurence Debroux, Director | ||
Lars Soerensen, CEO | ||
Marcus Schindler, Head EVP | ||
Stig Stroebaek, Director, Employee Representative | ||
Henrik Wulff, Executive Vice President Product Supply | ||
Thomas Koestler, Independent Director | ||
Lars Green, Executive Vice President Business Services & Compliance |
Novo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novo Nordisk a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.72 | |||
Return On Asset | 0.22 | |||
Profit Margin | 0.31 % | |||
Operating Margin | 0.43 % | |||
Current Valuation | 292.82 B | |||
Shares Outstanding | 1.72 B | |||
Shares Owned By Institutions | 38.87 % | |||
Price To Earning | 41.24 X | |||
Price To Book | 26.64 X | |||
Price To Sales | 1.73 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novo Nordisk in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novo Nordisk's short interest history, or implied volatility extrapolated from Novo Nordisk options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Novo Pink Sheet analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |